|
Sign In to gain access to subscriptions and/or personal tools.
|
A vascular Osteonecrosis in Patients with SLE: Relation to Corticosteroid Therapy and Anticardiolipin Antibodies
Sergio Migliaresi
Institute of Clinical Medicine - Rheumatology, 2nd University of Naples, Italy
Ugo Picillo
Institute of Clinical Medicine - Rheumatology, 2nd University of Naples, Italy
Lucia Ambrosone
Institute of Clinical Medicine - Rheumatology, 2nd University of Naples, Italy
Gaetano Di Palma
Institute of Clinical Medicine - Rheumatology, 2nd University of Naples, Italy
Matteo Mallozzi
Institute of Clinical Medicine - Rheumatology, 2nd University of Naples, Italy
Elena R. Tesone
Institute of Clinical Medicine - Rheumatology, 2nd University of Naples, Italy
Giuseppe Tirri
Institute of Clinical Medicine - Rheumatology, 2nd University of Naples, Italy
Sixty-nine unselected SLE patients were studied to evaluate the prevalence of avascular osteonecrosis (AVN) and its relationship with steroid therapy and with anticardiolipin antibodies (aCL). All the patients were under treatment with corticosteroids. AVN occurred in seven of the 69 patients (10. 14%) and was not related to corticosteroid intake. Seventeen of the 69 patients were also treated with methylprednisolone pulse therapy (MPPT) and cumulated the highest corticosteroid doses but none of them suffered from AVN. Excluding the 17 MPPT-treated SLE patients, corticosteroid intake was significantly higher in the AVN-SLE patients.
Abnormal IgG and/or IgM aCL serum levels were found in two of the seven AVN-SLE patients and in 24 of the 62 non-AVN SLE, without a statistically significant difference. None of the seven AVN-SLE patients showed features of antiphospholipid syndrome.
We conclude that in SLE patients a continuous high-dose steroid treatment may be considered a risk factor for AVN. On the contrary, MPPT regimen may reduce this risk. Anticardiolipin antibodies might represent an added factor which could play a role in some patients but not in all.
Key Words: Avascular osteonecrosis • SLE • Corticosteroid therapy • Anticardiolipin antibodies
Lupus, Vol. 3, No. 1,
37-41 (1994)
DOI: 10.1177/096120339400300108
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
L.T. Hiraki, J. Hamilton, and E.D. Silverman
Review: Measuring permanent damage in pediatric systemic lupus erythematosus
Lupus,
August 1, 2007;
16(8):
657 - 662.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S.C.M.S. Fialho, E. Bonfa, L.F. Vitule, E. D'Amico, V. Caparbo, S. Gualandro, and R.M.R. Pereira
Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus
Lupus,
April 1, 2007;
16(4):
239 - 244.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R Prasad, D Ibanez, D Gladman, and M Urowitz
The role of non-corticosteroid related factors in osteonecrosis (ON) in systemic lupus erythematosus: a nested case-control study of inception patients
Lupus,
March 1, 2007;
16(3):
157 - 162.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. Marulanda, T. M. Seyler, N. H. Sheikh, and M. A. Mont
Percutaneous drilling for the treatment of secondary osteonecrosis of the knee
J Bone Joint Surg Br,
June 1, 2006;
88-B(6):
740 - 746.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Calvo-Alen, G McGwin, S Toloza, M Fernandez, J M Roseman, H M Bastian, E J Cepeda, E B Gonzalez, B A Baethge, B J Fessler, et al.
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study
Ann Rheum Dis,
June 1, 2006;
65(6):
785 - 790.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Mundo, P Peris, A Monegal, M Navasa, R Cervera, and N Guanabens
Multifocal avascular necrosis after liver transplantation: an unusual presentation of the antiphospholipid syndrome
Lupus,
May 1, 2006;
15(5):
304 - 307.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S Vasoo, S Sangle, M Zain, D D'Cruz, and G Hughes
Orthopaedic manifestations of the antiphospholipid (Hughes) syndrome
Lupus,
May 1, 2005;
14(5):
339 - 345.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L M. Campos, M H Kiss, E A D'Amico, and C A A. Silva
Antiphospholipid antibodies and antiphospholipid syndrome in 57 children and adolescents with systemic lupus erythematosus
Lupus,
November 1, 2003;
12(11):
820 - 826.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C C Mok and C S Lau
Lupus in Hong Kong Chinese
Lupus,
September 1, 2003;
12(9):
717 - 722.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Y Molad, A Gorshtein, A J Wysenbeek, D Guedj, R Majadla, A Weinberger, and M Amit-Vazina
Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort{
Lupus,
June 1, 2002;
11(6):
356 - 361.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K Oinuma, Y Harada, Y Nawata, K Takabayashi, I Abe, K Kamikawa, and H Moriya
Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment
Ann Rheum Dis,
December 1, 2001;
60(12):
1145 - 1148.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W W Chatham and R P Kimberly
Treatment of lupus with corticosteroids
Lupus,
March 1, 2001;
10(3):
140 - 147.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M Y Mok, V T Farewell, and D A Isenberg
Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: Is there a role for antiphospholipid antibodies?
Ann Rheum Dis,
June 1, 2000;
59(6):
462 - 467.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. J. Wolfe and K. L. Taylor-Butler
Avascular Necrosis: A Case History and Literature Review
Arch Fam Med,
March 1, 2000;
9(3):
291 - 294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Zonana-Nacach, A Camargo-Coronel, P Yanez, M de Lourdes Sanchez, F J Jaimenez-Balderas, J Aceves-Avila, P Martinez-Osuna, J Fuentes, F Medina, and A Fraga
Measurement of damage in 210 Mexican patients with systemic lupus erythematosus: relationship with disease duration
Lupus,
February 1, 1998;
7(2):
119 - 123.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J S Sheikh, G S Retzinger, and E V Hess
Association of osteonecrosis in systemic lupus erythematosus with abnormalities of fibrinolysis
Lupus,
January 1, 1998;
7(1):
42 - 48.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Rascu, K. Manger, H-G. Kraetsch, J. Kalden, and B. Manger
Review : Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation?
Lupus,
August 1, 1996;
5(4):
323 - 327.
[Abstract]
[PDF]
|
|
|
|
|
